Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD trial of prolonged prophylactic antibiotics after pancreaticoduodenectomy
jRCTs051260181Phase 3Recruiting
- Start
- Sep 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of piperacillin + tazobactam in Periampullary Carcinoma (2 arms). Primary endpoint: Incidence of surgical site infection within 30 days after surgery. Started Sep 2026; status: recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
Periampullary Carcinoma
Beyond the preview
Go deeper on jRCTs051260181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260181.